Guanfacine Uses
Links shared publicly online about this topic
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants For The Treatment Of ADHD
medicalnewstoday.com — “Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (gu” View full resource at medicalnewstoday.com
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants F... http://bit.ly/ePyJtA #adhd
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
Google Sidewiki entry about Intuniv for ADHD: Understanding Tenex, Guanfacine and Alpha 2
google.com — “Some very interesting comments and updates are following the ADHD crew here - some useful points on Intuniv as well as the larger question of specific testing.” View full resource at google.com
Most Recently Shared on January 17, 2010 at 11:15 pm By:
Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." /> Dr Charles Parker Active Health Library, Doctor, Psychiatrist, and Physician
Over 100 Comments-Sidewiki entry on "Intuniv for ADHD: Understanding Tenex, Guanfacine and Alpha 2" http://bit.ly/78jSJq
PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
pharmalive.com — “PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents” View full resource at pharmalive.com
Most Recently Shared on February 28, 2011 at 7:27 pm By:
PharmaLive Pharma and Health News
Daily Advantage - FDA OKs Wider Intuniv Use - http://tinyurl.com/4on7zsc
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
GXR may be effective cotreatment for ADHD
pediatricsupersite.com — “When used in conjunction with psychostimulants, the selective alpha-2A-agonist guanfacine extended release (GXR) may offer a safe and effecti” View full resource at pediatricsupersite.com
Most Recently Shared on May 28, 2010 at 4:37 pm By:
Peter H Brown Doctor and Psychologist
GXR may be effective cotreatment for ADHD http://bit.ly/dn68sF #ADHD
Intuniv gains indication as adjunctive therapy in ADHD - ONA
oncologynurseadvisor.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 28, 2011 at 3:40 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Intuniv gains indication as adjunctive therapy in ADHD http://goo.gl/fb/srbUs
Intuniv gains indication as adjunctive therapy in ADHD - MPR
empr.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at empr.com
Most Recently Shared on February 28, 2011 at 3:44 pm By:
MPR News: Intuniv gains indication as adjunctive therapy in ADHD: Shire announced that the FDA has approved Intu... http://bit.ly/eyR7Gr
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Catherine K
Work in health publishing field. Passionate about healthy living.
-
Catherine K
Work in health publishing field. Passionate about healthy living.
-
Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." />
Dr Charles Parker
Dr. Parker is an Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally.
Advertisement
